The ability of [18F]- SiF Alin - TATE to image neuroendocrine tumors using a PET-Scan compared with [18F] - FDOPA imaging
Phase 1
- Conditions
- Imaging capabilities of the drug on patients with neuro endocrine tumors for better investigationsTherapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2021-002161-17-CY
- Lead Sponsor
- GERMAN ONCOLOGY CENTER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patients ith NET
Older than 18
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 15
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 5
Exclusion Criteria
Pregnant
Not consented
Simultaneously other tumor
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method